🇺🇸 Clostridium butyricum capsules in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Body Temperature Fluctuation — 1 report (16.67%)
- Diarrhoea — 1 report (16.67%)
- Gastroenteritis — 1 report (16.67%)
- Nausea — 1 report (16.67%)
- Nodal Rhythm — 1 report (16.67%)
- Pneumonia — 1 report (16.67%)
Other Gastroenterology approved in United States
Frequently asked questions
Is Clostridium butyricum capsules approved in United States?
Clostridium butyricum capsules does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Clostridium butyricum capsules in United States?
The Affiliated Hospital of Qingdao University is the originator. The local marketing authorisation holder may differ — check the official source linked above.